News for Denali Therapeutics Inc. (DNLI)

Denali Therapeutics (DNLI) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Denali Therapeutics (DNLI) has been the subject of a recent analyst report issued by B of A Securities. The firm, represented by analyst Tazeen Ahmad, has maint

A BofA analyst has revised the price target for Denali Therapeutics (DNLI), decreasing it from $28 to $27 while maintaining a Buy rating. The adjustment follows

Denali Therapeutics Inc's innovative approach to neurodegenerative diseases positions it as a key player in biotechnology.Strategic collaborations and a robust

SOUTH SAN FRANCISCO, Calif., May 06, 2025 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. ( DNLI) today reported financial results for the first quarter ended Ma

Wall Street showed mixed performance on Wednesday, April 2, 2025, as investors anxiously awaited President Donald Trump's

U.S. stock markets displayed cautious trading on Wednesday, April 2, 2025, as investors braced for President Trump's highly anticipated tariff announcement

Gene therapy is a medical approach that entails changing or modifying genes to treat or prevent disease.

Despite past failures, Denali's extensive pipeline and solid financial runway make it a compelling buy at current low stock prices. Learn more on DNLI stock here.

Market News Alerts Reports: NeuroSense Therapeutics Ltd. (NASDAQ: NRSN)* has announced significant progress toward the early commercialization of PrimeC in Can

PESG Research releases a new report covering NeuroSense Therapeutics (NASDAQ: NRSN)* and its recent developments: In a medical landscape hungry for innovation,

We recently compiled a list of the Jeff Bezos Investments in 2025: 12 Companies Bezos Is Investing In. In this article, we are going to take a look at where Denali Therapeutics Inc.

Denali Therapeutics Inc (DNLI) showcases a robust pipeline with innovative blood-brain barrier platform technologies.Despite being in the clinical stage, DNLI

On February 27, 2025, Denali Therapeutics Inc (DNLI) released its financial results for the fourth quarter and full year ending December 31, 2024. The company h

SOUTH SAN FRANCISCO, Calif., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. ( DNLI) today reported financial results for the fourth quarter and ye

**media[552840]**

On December 31, 2024, Baillie Gifford (Trades, Portfolio) made a significant move in its investment portfolio by reducing its position in Denali Therapeutics In

**media[534402]**

Summary Denali Therapeutics Inc (DNLI) has released promising long-term data from its Phase 1/2 study of tividenofusp alfa (DNL310) for treating Hunter syndrome